Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

In October, the Centers for Disease Control and Prevention recommended that high-risk adults get a second updated Covid ...

Sen. Rand Paul pointed to CDC guidance on child COVID-19 vaccinations, suggesting that people are "hesitant to believe" the ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

Pfizer's earnings were better than investors and management ... Its antiviral pill for treating COVID-19, Paxlovid, and its COVID vaccine, Comirnaty, are also performing a bit more strongly than it ...

Onyema Ogbuagu, an expert in infectious diseases and a Nigerian-born doctor, was central in Pfizer’s development of a ...

On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.